UK - London

LIVESCIENCE.COM   by Rachael Rettner                                                                         Feb. 13, 2015

Doctors who take care of very sick Ebola patients may feel socially isolated, but surprisingly, they may not feel more stressed than usual, a new study from Germany suggests.

Researchers surveyed 46 health care workers who treated Germany's first Ebola patient in August 2014, as well as 40 health care workers who worked in the same hospital but did not treat the Ebola patient.

The researchers who did the study hypothesized that the people who treated the Ebola patient would have more symptoms of psychological distress because they were working in a challenging environment that presented a risk that they could become infected with the deadly virus.

THE PRESS ASSOCIATION                               Feb. 4, 2015
LONDON --A British nurse who contracted Ebola while working in Sierra Leone possibly caught the virus by wearing a visor and not goggles, an investigation has suggested.
Press Association - Save the Children said Pauline Cafferkey, pictured on her return to health, may have contracted Ebola by wearing a visor rather than goggles when treating patients in Sierra Leone

The report by Save the Children said it cannot be completely certain how Pauline Cafferkey contracted Ebola but said both pieces of equipment are "equally safe".

The nurse, from Cambuslang in South Lanarkshire, had volunteered with the charity at the Ebola Treatment Centre (ETC) in Kerry Town before returning to the UK in December....

Save the Children published the findings of an independent review into the possible causes of how the 39-year-old caught the virus. The report said both visors and goggles are safe but there are slight differences in the type of clothing worn with each and in the protocols for putting them on and removing them....

Read complete story.

REUTERS     by Ben Hirschler                              Jan. 6, 2015
LONDON --Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.

The initiation of the Phase I study in Britain, which had been expected about now, marks further progress in the race to develop a vaccine against a disease that has killed more than 8,000 people in West Africa since last year.

Two other experimental vaccines, one from GlaxoSmithKline and a rival from NewLink and Merck, are already in clinical development. However, the J&J vaccine offers a different approach, since it involves two separate injections.

Read complete story.

http://www.reuters.com/article/2015/01/06/us-health-ebola-vaccine-j-j-idUSKBN0KF0HH20150106